DDInter1763 DDInter1070
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Linagliptin
Temsirolimus {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Temsirolimus {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Temsirolimus {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Temsirolimus {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linagliptin
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Alogliptin {u} (Compound) resembles {v} (Compound) Linagliptin
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Linagliptin
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Temsirolimus (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Linagliptin (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound) and Alogliptin (Compound) resembles Linagliptin (Compound)
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Temsirolimus (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Alogliptin (Compound) and Alogliptin (Compound) resembles Linagliptin (Compound)
Temsirolimus (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Temsirolimus (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Linagliptin
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Linagliptin (Compound)